Avid Radiopharmaceuticals, Inc.
Philadelphia
Pennsylvania
United States
Tel: 215-966-6208
Website: http://www.avidrp.com/
Email: skovronsky@avidrp.com
51 articles about Avid Radiopharmaceuticals, Inc.
-
Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease
5/28/2020
TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD)
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Eli Lilly and Company and its wholly-owned subsidiary Avid Radiopharmaceuticals, announced the successful Phase III trial of a Positron Emission Tomography (PET) imaging agent, flortaucipr F 18, in identifying tau in the brains of late-stage Alzheimer’s patients.
-
Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent
9/5/2018
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. today announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis.
-
As Jan Lundberg exits as president of Lilly Research Laboratories, the incoming boss, Dan Skovronsky, discussed the changes in direction he plans for Eli Lilly’s research business.
-
Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly and Company’s Acquisition of Avid Radiopharmaceuticals, Inc.
4/10/2012
-
Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly and Company's Acquisition of Avid Radiopharmaceuticals, Inc.
4/10/2012
-
Imaging Procedure Can Identify Biomarker Associated With Alzheimer's Disease, Avid Radiopharmaceuticals, Inc. Study
1/26/2011
-
Eli Lilly and Company Completes $300 Million Acquisition of Avid Radiopharmaceuticals, Inc. and Announces Alzheimer's Imaging Agent to Get FDA Review
12/22/2010
-
Eli Lilly and Company to Acquire Avid Radiopharmaceuticals, Inc. in $800 Million Deal
11/9/2010
-
Avid Radiopharmaceuticals, Inc. Expands R&D Capabilities with Appointment of Dr. Mark A. Mintun as Chief Medical Officer
8/10/2010
-
Avid Radiopharmaceuticals, Inc. Amyloid Tracer Hits Target In Alzheimer's Study
7/12/2010
-
New Way To Detect Alzheimer's From Avid Radiopharmaceuticals, Inc.
6/24/2010
-
Avid Radiopharmaceuticals, Inc. to Present at the Inaugural Jefferies Global Life Sciences Conference on June 10th
6/7/2010
-
Avid Radiopharmaceuticals, Inc. to Present at the 9th Annual Needham Healthcare Conference on June 9th
6/3/2010
-
Avid Radiopharmaceuticals, Inc. to Present Clinical Trial Advances in Molecular Imaging of Pathologic Targets Associated with Alzheimer’s Disease, Dementia with Lewy Bodies and Diabetes at SNM Meeting June 6-9th
6/2/2010
-
Avid Radiopharmaceuticals, Inc. to Present at the Citi Global Health Care Conference on Wednesday, May 26
5/24/2010
-
Avid Radiopharmaceuticals, Inc.'s Positive Interim Results From Phase III Trial of Amyloid Imaging Agent Florbetapir F18 Presented at American Academy of Neurology Annual Meeting
4/15/2010
-
Avid Radiopharmaceuticals, Inc. and Siemens PETNET Solutions Collaborate on Manufacturing of ß-amyloid Imaging Agent, Florbetapir F 18 (18F-AV-45)
4/7/2010
-
Avid Radiopharmaceuticals, Inc., Cardinal Health, Inc. Reach Milestone in Innovative Alzheimer's Research
3/25/2010